Patents by Inventor Eilyn R. Lacy

Eilyn R. Lacy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250163182
    Abstract: The present disclosure provides ENPP3 binding agents, including bispecific ENPP3×CD3 binding proteins, and related compositions and methods of use.
    Type: Application
    Filed: August 6, 2024
    Publication date: May 22, 2025
    Inventors: Smruthi Vijayaraghavan, Eilyn R. Lacy, Yoshitomo Hamuro
  • Patent number: 12234280
    Abstract: Monoclonal anti-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies. The antibodies of the invention may also be used to quantify tau in biological samples.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: February 25, 2025
    Assignee: Janssen Pharmaceutica NV
    Inventors: Kristof Van Kolen, Marc Mercken, Linda Barone, Eilyn R. Lacy, Rupesh Nanjunda, John Wheeler, Jinquan Luo, Marianne Borgers
  • Publication number: 20210002358
    Abstract: Monoclonal anti-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies. The antibodies of the invention may also be used to quantify tau in biological samples.
    Type: Application
    Filed: March 4, 2019
    Publication date: January 7, 2021
    Inventors: Kristof Van Kolen, Marc Mercken, Linda Barone, Eilyn R. Lacy, Rupesh Nanjunda, John Wheeler, Jinquan Luo, Marianne Borgers
  • Patent number: 10633435
    Abstract: Monoclonal anti-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies. The antibodies of the invention may also be used to quantify tau in biological samples.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: April 28, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Kristof Van Kolen, Marc Mercken, Linda Barone, Eilyn R. Lacy, Rupesh Nanjunda, John Wheeler, Jinquan Luo
  • Publication number: 20190270793
    Abstract: Monoclonal anti-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies. The antibodies of the invention may also be used to quantify tau in biological samples.
    Type: Application
    Filed: March 4, 2019
    Publication date: September 5, 2019
    Inventors: Kristof Van Kolen, Marc Mercken, Linda Barone, Eilyn R. Lacy, Rupesh Nanjunda, John Wheeler, Jinquan Luo
  • Publication number: 20090298186
    Abstract: A method for determining conformational stability of proteins detects the change in free sulfhydryls accessible to reaction with a fluorescent probe after combined chemical and thermal denaturation. The method is useful in any application where the stability and integrity of a protein preparation is useful information. The method can be used to screen protein variants for desirable stability profile.
    Type: Application
    Filed: February 27, 2009
    Publication date: December 3, 2009
    Inventors: Michael Brigham-Burke, Eilyn R. Lacy